Flexible Dosing of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Initial Results From the Real-World–Simulating Expanded Access Protocol Study, JADE REAL. J of Skin 2025, 9 (6), s618. https://doi.org/10.25251/t4rkzz84.